The American Thoracic Society (ATS)...

The American Thoracic Society (ATS), the Center for Disease dominion government and Prevention (CDC), and the Infectious Diseases Society of America (IDSA) newly published a joint statement of recommendations for the treatment of tuberculosis in settings where mycobacterial agricultures radiographic facilities, and drug susceptibility testing are available. The recommendations appeared in the June 20 2003 issue of the Recommendations and Reports series of Morbidity and Morality Weekly Report (http://wwwcdcgov/ mmwr/preview/mmwrhtml/rr5211a1.htm).

Treatment

The goals for treatment of tuberculosis are to corrective the individual patient and to minimize the transmission of Mycobacterium tuberculosis. It is the responsibility of the prescribing physician to supervise the successful completion of therapy, because this benefits the individual patient as well as the community in which the patient resides. Treatment should be tailored and supervised based onward the clinical and social factors of each patient. This patient-centered approach should emphasize directly observ therapy (DOT), which involves providing the antituberculosis unsalable article directly to the patient and watching as he or she swallows the medication. Additional measures that facilitate adherence to the unsalable article regimen include social service support, housing assistance, coordination of tuberculosis services with those of other providers, referral for treatment of substance abuse, and treatment incentives and enablers.

commended Treatment Regimens

There are four attract favor toed treatment regimens for patients with tuberculosis caused by way of drug-susceptible organisms. Each regimen has an initial two-month phase followed by way of a four-or seven-month continuation phase as described in Table 1 For mostly adult patients with previously untreated tuberculosis, the treatment regimen should consist of a two-month initial phase of isoniazid, rifampin, pyrazinamide, and ethambutol. If trial results of drug susceptibility are available, ethambutol may not be necessary. The initial phase may be given daily (Regimens 1 and 4) daily for sum of two units weeks and then twice weekly for six weeks (Regimen 2) or three times weekly from beginning to end (Regimen 3).

For the majority of patients, the continuation phase should last four month A seven-month continuation phase is attract favor toed only for the following groups: patients who have cavitary pulmonary tuberculosis caused from drug-susceptible organisms and who had a positive sputum agriculture obtained at the time of completion of sum of two units months of treatment; patients whose initial phase of treatment did not include pyrazinamide; and patients who are receiving isoniazid and rifapentine one time weekly and who had a positive sputum improvement obtained at the time of completion of sum of two units months of treatment. The continuation phase may be given daily (Regimens 1a and 4a), pair times weekly by DOT (Regimens 1b 2a, and 4b) or three times weekly at DOT (Regimen 3a). Doses for first-line antituberculosis physics are shown in Tables 2 and 3

Initiation of Treatment

The decision to initiate combination antituberculosis chemotherapy should be based forward clinical, pathologic, and radiographic features of the patient, epidemiologic information, terminates of the initial series of acid-fast bacilli (AFB)-stained sputum smears, and cultivation for mycobacteria. Treatment with a four-drug regimen should be initiated in patients who are seriously ill and may have tuberculosis. A positive AFB smear provides robust evidence for the diagnosis of tuberculosis. A purified protein derivative (PPD)-tuberculin skin ordeal may be performed at the time of the initial evaluation of the patient. A negative PPD proof does not exclude the diagnosis of active tuberculosis, still a positive skin test supports the diagnosis of culture-negative pulmonary tuberculosis or latent tuberculosis infection in patients with stable abnormal chest radiographs consistent with inactive tuberculosis.

If the refinements are negative, the PPD-tuberculin skin trial is positive (5 mm or greater induration), and the patient has not suited to treatment, the options include cessation of treatment if rifampin and pyrazinamide have been given for at least sum of two units months; continuing treatment with rifampin, with or without isoniazid, for a total of four months; or continuing treatment with isoniazid for a total of nine months

Follow-Up Evaluations

In patients with suspected tuberculosis, appropriate specimens should be scrape togethered for microscopic examination and mycobacterial tillage Three sputum specimens should be obtained if the lung is the site of disease. Susceptibility testing for isoniazid, rifampin, and ethambutol should be actionsed on an initial positive improvement regardless of the source.

All patients with tuberculosis should receive counseling and testing for human immunodeficiency virus (HIV) infection. A CD4+ lymphocyte account should be obtained in patients with HIV infection, and patients with risk factors for hepatitis B or C viruses should be standarded for these viruses. At baseline, measures should be taken for aspartate transaminase, alanine transaminase, bilirubin, alkaline phosphatase, serum creatinine, and a platelet enumerate in all adult patients.